Targeting endosomal acidification by chloroquine analogs as a promising strategy for the treatment of emerging viral diseases - PubMed (original) (raw)

Review

. 2017 Jan 23;5(1):e00293.

doi: 10.1002/prp2.293. eCollection 2017 Feb.

Affiliations

Review

Targeting endosomal acidification by chloroquine analogs as a promising strategy for the treatment of emerging viral diseases

Md Abdul Alim Al-Bari. Pharmacol Res Perspect. 2017.

Abstract

Emerging viruses such as HIV, dengue, influenza A, SARS coronavirus, Ebola, and other viruses pose a significant threat to human health. Majority of these viruses are responsible for the outbreaks of pathogenic lethal infections. To date, there are no effective therapeutic strategies available for the prophylaxis and treatment of these infections. Chloroquine analogs have been used for decades as the primary and most successful drugs against malaria. Concomitant with the emergence of chloroquine-resistant Plasmodium strains and a subsequent decrease in the use as antimalarial drugs, other applications of the analogs have been investigated. Since the analogs have interesting biochemical properties, these drugs are found to be effective against a wide variety of viral infections. As antiviral action, the analogs have been shown to inhibit acidification of endosome during the events of replication and infection. Moreover, immunomodulatory effects of analogs have been beneficial to patients with severe inflammatory complications of several viral diseases. Interestingly, one of the successful targeting strategies is the inhibition of HIV replication by the analogs in vitro which are being tested in several clinical trials. This review focuses on the potentialities of chloroquine analogs for the treatment of endosomal low pH dependent emerging viral diseases.

Keywords: Chloroquine analogs; antiviral actions; endosomal pH and viral replication.

PubMed Disclaimer

Figures

Figure 1

Figure 1

Inhibition of viral infection with the increase

pH

by chloroquine analogs ((Al‐Bari 2015). Steps: 1. Endosome formation; 2. Fusion; 3. posttranslational modification; 4. uncoating virus and CQ, chloroquine.

Similar articles

Cited by

References

    1. Accapezzato D, Visco V, Francavilla V, Molette C, Donato T, Paroli M, et al. (2005). Chloroquine enhances human CD8 + T cell responses against soluble antigens in vivo. J Exp Med 202: 817–828. - PMC - PubMed
    1. Adachi K, Ichinose T, Takizawa N, Watanabe K, Kitazato K, Kobayashi N (2007). Inhibition of betanodavirus infection by inhibitors of endosomal acidification. Arch Virol 152: 2217–2224. - PMC - PubMed
    1. Al‐Bari MA (2015). Chloroquine analogues in drug discovery: new directions of uses, mechanisms of actions and toxic manifestations from malaria to multifarious diseases. J Antimicrob Chemother 70: 1608–1621. - PMC - PubMed
    1. Ashfaq UA, Javed T, Rehman S, Nawaz Z, Riazuddin S (2011). Lysosomotropic agents as HCV entry inhibitors. Virol J 8: 163. - PMC - PubMed
    1. Augustijns P, Geusens P, Verbeke N (1992). Chloroquine levels in blood during chronic treatment of patients with rheumatoid arthritis. Eur J Clin Pharmacol 42: 429–433. - PubMed

Publication types

LinkOut - more resources